Viz.ai Forms Alliance to Expand Access to AI-Powered Subdural Hemorrhage Care

Viz.ai has forged a strategic commercialization collaboration with Johnson & Johnson to expand access to Viz.ai’s Subdural Hemorrhage software solution across U.S. hospitals for automated detection, labeling, and quantification of subdural collections. By integrating the Viz Subdural solution into its neurovascular offerings, the company is helping hospitals identify appropriate patients and streamline care pathways for suspected chronic subdural hematoma (cSDH), from detection through treatment and follow-up.

The Viz Subdural solution includes U.S. Food and Drug Administration-cleared algorithms for detecting subdural hemorrhage, and automated labeling, visualization, and quantification of collections in the subdural space. The solution is powered by the Viz.ai platform, including Viz Assist, which provides artificial intelligence (AI)-driven chart summarization to help clinicians quickly contextualize imaging findings within the broader clinical picture. By surfacing relevant patient history, medications, and prior notes, Viz Assist reduces manual chart review and accelerates clinical decision-making to enable faster, more informed care coordination.

“Chronic subdural hematoma is a growing condition with a novel therapeutic procedure, MMA embolization, that has been proven effective,” Viz.ai Co-Founder/CEO Chris Mansi, M.D., said. “By collaborating with Johnson & Johnson, we are expanding access to AI-powered detection and coordination tools, including Viz Assist, that may help clinical teams identify patients earlier, align multidisciplinary care, and ultimately support better outcomes for patients undergoing treatment for cSDH.”

The collaboration aims to help surface suspected cSDH earlier and standardize point-of-care severity assessment so clinicians can coordinate across specialties and more reliably identify patients who may benefit from middle meningeal artery (MMA) embolization.

Viz.ai develops AI-powered care coordination and clinical workflow solutions, which are deployed in 2,000 U.S. hospitals and trusted by life sciences companies. Its platform combines real-time, multimodal clinical data with deep clinician engagement to detect disease earlier, coordinate care teams, and help ensure patients receive the proper treatment faster. Viz.ai was the first company awarded CMS reimbursement for AI and is ranked the top healthcare AI platform by hospitals and health systems in the Black Book Research survey.